Your session is about to expire
← Back to Search
Ketone Ester
AN OPEN-LABEL, ACUTE CLINICAL TRIAL TO ASSESS THE LEVEL OF KETONE PRODUCTION FOLLOWING CONSUMPTION OF AVELA™ (R)-1,3-BUTANEDIOL IN AN ADULT POPULATION
N/A
Waitlist Available
Research Sponsored by Genomatica Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 0, 30, 60, 90, 120, 180, 240, and 300 minutes
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a special drink containing (R)-1,3-butanediol to see how it affects ketone levels in the blood. It also looks at how the drink impacts stomach comfort and alertness. The body turns (R)-1,3-butanediol into ketones, which can be used for energy.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 0, 30, 60, 90, 120, 180, 240, and 300 minutes
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~0, 30, 60, 90, 120, 180, 240, and 300 minutes
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
To evaluate the level of production of BHB measure of blood ketones levels (i.e., blood BHB levels)
Secondary study objectives
To assess GI symptomology
To assess Sleepiness/alertness
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Avela™ (R)-1,3-ButanediolExperimental Treatment1 Intervention
3 servings of Avela™, with consumption of each serving separated by 30 minutes and each serving providing 11.5 g of (R)-1,3-butanediol \[total intake of 34.5 g of (R)-1,3-butanediol\].
Find a Location
Who is running the clinical trial?
Genomatica Inc.Lead Sponsor